FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

716125002: Pembrolizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jul 2016. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3304810011 Pembrolizumab (substance) en Fully specified name Active Entire term case insensitive SNOMED CT core module
3304811010 Pembrolizumab en Synonym Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Pembrolizumab Is a Antineoplastic agent true Inferred relationship Existential restriction modifier
Pembrolizumab Is a Monoclonal antibody agent false Inferred relationship Existential restriction modifier
Pembrolizumab Is a Monoclonal antibody true Inferred relationship Existential restriction modifier
Pembrolizumab Is a Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) true Inferred relationship Existential restriction modifier
Pembrolizumab Has disposition Programmed cell death protein 1 inhibitor true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing pembrolizumab Has active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier 1
Product containing pembrolizumab in parenteral dose form (medicinal product form) Has active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier 1
Pembrolizumab Has active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier 1
Product containing only pembrolizumab in parenteral dose form (medicinal product form) Has active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier 1
Product containing precisely pembrolizumab 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) Has precise active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier 1
Product containing precisely pembrolizumab 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) Has basis of strength substance True Pembrolizumab Inferred relationship Existential restriction modifier 1
Product containing precisely pembrolizumab 25 milligram/1 milliliter conventional release solution for injection (clinical drug) Has precise active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier 1
Product containing precisely pembrolizumab 25 milligram/1 milliliter conventional release solution for injection (clinical drug) Has basis of strength substance True Pembrolizumab Inferred relationship Existential restriction modifier 1
Keytruda 100mg/4ml concentrate for solution for infusion vials (Originalis B.V.) 1 vial Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 100mg/4ml concentrate for solution for infusion vials (Originalis B.V.) Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 50mg powder for concentrate for solution for infusion vials (Organon Pharma (UK) Ltd) Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Pembrolizumab 50mg powder for solution for infusion vials 1 vial Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Pembrolizumab 50mg powder for solution for infusion vials Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 50mg powder for concentrate for solution for infusion vials (Organon Pharma (UK) Ltd) 1 vial Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Pembrolizumab 100mg/4ml solution for infusion vials Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 100mg/4ml concentrate for solution for infusion vials (Merck Sharp & Dohme (UK) Ltd) Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Pembrolizumab 100mg/4ml solution for infusion vials 1 vial Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 100mg/4ml concentrate for solution for infusion vials (Merck Sharp & Dohme (UK) Ltd) 1 vial Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 50mg powder for concentrate for solution for infusion vials (Originalis B.V.) Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier
Keytruda 50mg powder for concentrate for solution for infusion vials (Originalis B.V.) 1 vial Has specific active ingredient True Pembrolizumab Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start